These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38808531)

  • 1. Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa.
    Ciurescu D; Condruz S; Irimie M
    Acta Dermatovenerol Alp Pannonica Adriat; 2024 Sep; 33(3):145-149. PubMed ID: 38808531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
    Vasilev P; Kalev D; Karamanliev M; Dimitrov D; Troyanova P; Yordanova I
    J Dtsch Dermatol Ges; 2023 Mar; 21(3):295-297. PubMed ID: 36855845
    [No Abstract]   [Full Text] [Related]  

  • 3. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
    Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
    Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
    Santucci C; Alexandru M; Chen X; Mellerio JE; Karagiannis SN; Jacków-Malinowska J
    Hum Immunol; 2024 May; 85(3):110805. PubMed ID: 38703415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial.
    Woodley DT; Hao M; Kwong A; Levian B; Cogan J; Hou Y; Mosallaei D; Kleinman E; Zheng K; Chung C; Kim G; Peng D; Chen M
    Br J Dermatol; 2024 Jul; 191(2):267-274. PubMed ID: 38366625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
    Reimer A; Lu S; He Y; Bruckner-Tuderman L; Technau-Hafsi K; Meiss F; Has C; von Bubnoff D
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):e1-e3. PubMed ID: 31374134
    [No Abstract]   [Full Text] [Related]  

  • 7. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
    Arnold AW; Bruckner-Tuderman L; Zuger C; Itin PH
    Dermatology; 2009; 219(1):80-3. PubMed ID: 19439919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inherited epidermolysis bullosa dystrophica and squamous cell carcinoma- A case report.
    Gayathri E; Anbukkarasi K; Lilly SM
    Indian J Pathol Microbiol; 2023; 66(2):360-362. PubMed ID: 37077084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.
    Piccerillo A; El Hachem M; De Vito R; De Luca EV; Peris K
    JAMA Dermatol; 2020 Jun; 156(6):708-710. PubMed ID: 32320041
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
    Kim M; Murrell DF
    Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion.
    Pourreyron C; Chen M; McGrath JA; Salas-Alanis JC; South AP; Leigh IM
    Br J Dermatol; 2014 Jun; 170(6):1256-65. PubMed ID: 24641191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases.
    Hwang A; Kwon A; Miller CH; Reimer-Taschenbrecker A; Paller AS
    Orphanet J Rare Dis; 2024 May; 19(1):206. PubMed ID: 38769503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
    Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl.
    Shivaswamy KN; Sumathy TK; Shyamprasad AL; Ranganathan C
    Int J Dermatol; 2009 Jul; 48(7):731-3. PubMed ID: 19570079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
    Kim M; Li M; Intong LR; Tran K; Melbourne W; Marucci D; Bucci J; de Souza P; Mallesara G; Murrell DF
    Br J Dermatol; 2013 Jul; 169(1):208-10. PubMed ID: 23398414
    [No Abstract]   [Full Text] [Related]  

  • 16. Morphological and morphometric analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a retrospective study.
    Filoni A; Cicco G; Lospalluti L; Maglietta A; Foti C; Annichiarico G; Resta L; Bonamonte D
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1707-1714. PubMed ID: 31692111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 13-year-old girl with recessive dystrophic epidermolysis bullosa presenting with squamous cell carcinoma.
    Ayman T; Yerebakan O; Ciftçioglu MA; Alpsoy E
    Pediatr Dermatol; 2002; 19(5):436-8. PubMed ID: 12383103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
    Duong T; Wong D; Barrett A; Price H
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
    Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
    Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa-Hallopeau-Siemens: a report of four cases.
    Dammak A; Zribi J; Boudaya S; Mseddi M; Meziou TJ; Masmoudi A; Ellouze Z; Keskes H; Turki H
    Int J Dermatol; 2009 Jun; 48(6):588-91. PubMed ID: 19538366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.